An ultrasound-based treatment for prostate cancer showed better safety and operative metrics versus robotic radical ...

(NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-3 study of TALZENNA ® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI ® ...

Brian Holmes is the first man in the UK and the fifth in the world to receive the treatment.

Top experts share the latest bladder, kidney and prostate cancer advances from the 2026 ASCO GU Symposium, highlighting ...

While sales of Talzenna, which Pfizer acquired in a $14 billion deal, have been “negligible” so far, the new results should ...

Watchdog finds failings in prostate cancer treatment in North Wales going back almost a decade.

The effects of the extent of lymph node dissection during radical prostatectomy on prostate cancer survival outcomes have been unclear, pending long-term follow-up data from randomized controlled ...

A new immunotherapy drug has demonstrated early promise in a recent prostate cancer clinical trial. The drug, called VIR-5500, is a "masked T-cell engager." This type of immunotherapy ignites our own ...

The addition of Zytiga (abiraterone) to Truqap (capivasertib) significantly prolonged radiographic progression-free survival (rPFS) in patients with PTEN-deficient metastatic hormone-sensitive ...

Germline testing can identify hereditary cancer, which leads to implications for family members, cascade testing for relatives, and starting surveillance and prevention measures: Genetic testing in ...

Results challenge view that high testosterone fuels prostate cancer growth ...

Read more about the factors that patients with prostate cancer value most in treatment decisions, as reported at EAU 2026.